Chemistry:Sembragiline
From HandWiki
Sembragiline (INN, USAN; developmental code names EVT-302, RG-1577, RO-4602522) is a selective and reversible monoamine oxidase B (MAO-B) inhibitor which is or was under development for the treatment of Alzheimer's disease.[1][2][3][4] It was also under development for the treatment of smoking withdrawal, but development for this indication was discontinued.[1][2][3] The drug is taken by mouth.[1][4] Sembragiline is or was being developed by Roche and Evotec SE.[1][2][3]
References
- ↑ 1.0 1.1 1.2 1.3 "Sembragiline". 5 November 2023. https://adisinsight.springer.com/drugs/800026046.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Sembragiline with Synapse". 22 February 2025. https://synapse.patsnap.com/drug/8108b821cdc44078b0b1a7cda8454c45.
- ↑ 3.0 3.1 3.2 "Sembragiline". 20 November 2015. https://www.alzforum.org/therapeutics/sembragiline.
- ↑ 4.0 4.1 "The Development of Pharmacological Therapies for Alzheimer's Disease". Neurology and Therapy 10 (2): 609–626. December 2021. doi:10.1007/s40120-021-00282-z. PMID 34532845. "Sembragiline (also known as RO4602522, RG1577 and EVT302) is a potent, selective and reversible monoamine oxidase B (MAO-B) inhibitor developed to treat AD. A PET study revealed almost complete inhibition of central MAO-B at an oral dose of 1 mg per day in AD patients; however, no cognitive benefits were detected after treatment [91].".
 |  |
